US equities |
NVDA $240.65 ▲+0.73% SPCX $173.93 ▲+1.66% MU $1,067.90 ▲+0.37% MRVL $286.48 ▲+5.61% AMD $656.18 ▲+3.87% SNDK $1,675.40 ▼-1.69% AVGO $378.62 ▲+4.44% INTC $113.13 ▼-2.63%
FinancialContent

Endovia Health Sciences, Inc. Common Stock (NY:EDVA)

0.1594 -0.0065 (-3.92%)
Delayed Quote Updated: 12:34 PM EDT, Oct 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Endovia Health Sciences, Inc. Common Stock

News headline image
Endovia and Lupvindol BioSciences Announce FDA Determination that CannEpil® for Canine Bone Cancer Pain Qualifies as a Minor Use, Establishing Eligibility for Conditional Approval Pathway
Companies to Meet Formally with FDA’s Center for Veterinary Medicine on November 19th for Pre-Submission Conference; U.S. Manufacturing Strategy Underway to Support Potential 2027 Veterinary Product... 
From Endovia Health Sciences
Via GlobeNewswire
News headline image
Endovia Health Sciences Closes Initial Funding to Accelerate CannEpil® Development Amid Growing Federal Support for Botanical Drug Pathways
From Endovia Health Sciences
Via GlobeNewswire
News headline image
Endovia Health Sciences Welcomes Historic Shift in Federal Cannabinoid Policy; Advances CannEpil® FDA Submission and Expands Development Pipeline
From Endovia Health Sciences
Via GlobeNewswire
News headline image
Endovia Health Sciences, formerly Splash Beverage, Achieves First FDA Regulatory Milestone for CannEpil® Veterinary Development Program
FDA establishes Investigational New Animal Drug (INAD) File No. 14145, advancing the Company's companion-animal oncology program and marking first milestone under Lupvindol collaboration 
From Endovia Health Sciences
Via GlobeNewswire